1,180
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Assessment of early vascular changes in adult females with polycystic ovary syndrome: correlation with insulin resistance

, , , , , , , & show all
Article: 2210226 | Received 21 Feb 2023, Accepted 24 Apr 2023, Published online: 14 May 2023

References

  • Ding T, Hardiman PJ, Petersen I, et al. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):1–4.
  • Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010;95(5):2038–2049.
  • Moran LJ, Pasqual R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the androgen excess and polycystic ovary syndrome society. Fertil Steril. 2009;92(6):1966–1982.
  • Romano LGM, Bedoschi G, Melo AS, et al. Metabolic abnormalities in polycystic ovary syndrome women: obese and non -obese. Rev Bras Ginecol Obstet. 2011;33(6):310–316.
  • Karoli R, Fatima J, Siddiqi Z, et al. Study of early atherosclerotic markers in women with polycystic ovary syndrome. Indian J Endocrinol Metab. 2012;16(6):1004–1008.
  • Dube R. Does endothelial dysfunction correlate with endocrinal abnormalities in patients with polycystic ovary syndrome? Avicenna J Med. 2016;6(4):91–102.
  • Peters SA, den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012;98(3):177–184.
  • Chhabra N. Endothelial dysfunction – a predictor of atherosclerosis. Internet J Med Update. 2009;4:33–41.
  • Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–960.
  • Ibrahim T, Ali A, Radwan M. Lipid profile in women with polycystic ovary syndrome. Egypt J Hosp Med. 2020;78(2): 272–277.
  • Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7(2):207–215.
  • Jabbour R, Ott J, Eppel W, et al. Carotid intima-media thickness in polycystic ovary syndrome and its association with hormone and lipid profiles. PLoS One. 2020;15(4):e0232299.
  • Münzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis and prognostic implication of endothelial dysfunction. Ann Med. 2008;40(3):180–196.
  • Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285–1295.
  • Alexandraki K, Kandaraki E, Poulia KA, et al. Assessment of early markers of cardiovascular risk in polycystic ovary syndrome. touchREV Endocrinol. 2021;17(1):37–53.
  • Kravariti M, Kazakos N, Makrigiannakis A, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(9):5088–5095.
  • Krentowska A, Łebkowska A, Jacewicz-Święcka M, et al. Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome. Endocrine. 2021;72(2):400–410.
  • Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol (Oxf). 2013;78(3):438–446.
  • Moncada S. Endothelium and cardiovascular diseases. Vasc Biol Clin Syndromes. 2018;1:5–10.
  • Orio F, Jr, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(9):4588–4593.
  • Wanderley MS, Pereira LCR, Santos CB, et al. Association between insulin resistance and cardiovascular risk factors in polycystic ovary syndrome patients. Rev Bras Ginecol Obstet. 2018;40(4):188–195.
  • Lambert EA, Teede H, Sari CI, et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clin Endocrinol (Oxf). 2015;83(6):812–819.
  • Virdis A, Neves MF, Duranti E, et al. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des. 2013;19(13):2382–2389.
  • Freeman AM, Pennings N. Insulin resistance. In: StatPearls. [Internet]. Treasure Island (FL); StatPearls Publishing; 2021. 507839.